Page 283 - Read Online

Zhang et al. Hepatoma Res 2019;5:27 I http://dx.doi.org/10.20517/2394-5079.2019.13 Page 13 of 18

perspectives. Adv Exp Med Biol 2013;777:185-96.
24 Chiba T, Kita K, Zheng YW, Yokosuka O, Saisho H, et al. Side population purified from hepatocellular carcinoma cells harbors cancer
stem cell-like properties. Hepatology 2010;44:240-51.
25 Ma S, Chan KW, Lee TK, Tang KH, Wo JY, et al. Aldehyde dehydrogenase discriminates the CD133 liver cancer stem cell populations.
Mol Cancer Res 2008;6:1146-53.
26 Lan X, Wu YZ, Wang Y, Wu FR, Zang CB, et al. CD133 silencing inhibits stemness properties and enhances chemoradiosensitivity in
CD133-positive liver cancer stem cells. Int J Mol Med 2013;31:315-24.
27 Piao LS, Hur W, Kim TK, Hong SW, Kim SW, et al. CD133 + liver cancer stem cells modulate radioresistance in human hepatocellular
carcinoma. Cancer Lett 2012;315:129-37.
28 Suetsugu A, Nagaki M, Aoki H, Motohashi T, Kunisada T, et al. Characterization of CD133+ hepatocellular carcinoma cells as cancer
stem/progenitor cells. Biochem Biophys Res Commun 2006;351:820-4.
29 Ma S, Tang KH, Chan YP, Lee TK, Kwan PS, et al. miR-130b Promotes CD133 Liver Tumor-Initiating Cell Growth and Self-Renewal
via Tumor Protein 53-Induced Nuclear Protein 1. Cell Stem Cell 2010;7:694-707.
30 Ma S, Lee TK, Zheng BJ, Chan KW, Guan XY. CD133+ HCC cancer stem cells confer chemoresistance by preferential expression of the
Akt/PKB survival pathway. Oncogene 2008;27:1749-58.
31 Tong CM, Ma S, Guan XY. Biology of hepatic cancer stem cells. J Gastroenterol Hepatol 2011;26:1229-37.
32 Liu YM, Li XF, Liu H, Wu XL. Ultrasound-targeted microbubble destruction-mediated downregulation of CD133 inhibits epithelial-
mesenchymal transition, stemness and migratory ability of liver cancer stem cells. Oncol Rep 2015;34:2977-86.
33 Tang KH, Ma S, Lee TK, Chan YP, Kwan PS, et al. CD133(+) liver tumor-initiating cells promote tumor angiogenesis, growth, and self-
renewal through neurotensin/interleukin-8/CXCL1 signaling. Hepatology 2012;55:807-20.
34 Li J, Chen JN, Zeng TT, He F, Chen SP, et al. CD133+ liver cancer stem cells resist interferon-gamma-induced autophagy. BMC Cancer
2016;16:15.
35 Chen H, Luo Z, Sun W, Zhang C, Sun H, et al. Low glucose promotes CD133mAb-elicited cell death via inhibition of autophagy in
hepatocarcinoma cells. Cancer Lett 2013;336:204-12.
36 Piao LS, Hur W, Kim TK, Hong SW, Kim SW, et al. CD133+ liver cancer stem cells modulate radioresistance in human hepatocellular
carcinoma. Cancer Lett 2012;315:129-37.
37 Rountree CB, Ding W, He L, Stiles B. Expansion of CD133-expressing liver cancer stem cells in liver-specific phosphatase and tensin
homolog deleted on chromosome 10-deleted mice. Stem Cells 2009;27:290-9.
38 Jang JW, Song Y, Kim SH, Kim JS, Kim KM, et al. CD133 confers cancer stem-like cell properties by stabilizing EGFR-AKT signaling
in hepatocellular carcinoma. Cancer Lett 2017;389:1-10.
39 Hagiwara S, Kudo M, Nagai T, Inoue T, Ueshima K, et al. Activation of JNK and high expression level of CD133 predict a poor response
to sorafenib in hepatocellular carcinoma. Br J Cancer 2012;106:1997-2003.
40 Yang Z, Zhang L, Ma A, Liu L, Li J, et al. Transient mTOR inhibition facilitates continuous growth of liver tumors by modulating the
maintenance of CD133+ cell populations. PLoS One 2011;6:e28405.
41 You H, Ding W, Rountree CB. Epigenetic regulation of cancer stem cell marker CD133 by transforming growth factor-beta. Hepatology
2010;51:1635-44.
42 Chen CL, Tsukamoto H, Liu JC, Kashiwabara C, Feldman D, et al. Reciprocal regulation by TLR4 and TGF-β in tumor-initiating stem-
like cells. J Clin Invest 2013;123:2832-49.
43 Ezzeldin M, Borrego-Diaz E, Taha M, Esfandyari T, Wise AL, et al. RalA signaling pathway as a therapeutic target in hepatocellular
carcinoma (HCC). Mol Oncol 2014;8:1043-53.
44 Wang R, Li Y, Tsung A, Huang H, Du Q, et al. iNOS promotes CD24+ CD133+ liver cancer stem cell phenotype through a TACE/
ADAM17-dependent Notch signaling pathway. Proc Natl Acad Sci U S A 2018;115:E10127-E36.
45 Tang Y, Berlind J, Mavila N. Inhibition of CREB binding protein-beta-catenin signaling down regulates CD133 expression and activates
PP2A-PTEN signaling in tumor initiating liver cancer cells. Cell Commun Signal 2018;16:9.
46 Luk STC, Tong M, Ng KY, Yip KY-L, Guan XY, Ma S. Identification of ZFP42/REX1 as a regulator of cancer stemness in CD133+ liver
cancer stem cells by genome-wide DNA methylation analysis. AACR Annual Meeting 2018;DOI: 10.1158/1538-7445.
47 Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. 2012;12(4):252.
48 Chai S, Tong M, Ng KY, Kwan PS, Chan YP, et al. Regulatory role of miR-142-3p on the functional hepatic cancer stem cell marker
CD133. Oncotarget 2014;5:5725-35.
49 Huang H, Hu M, Li P, Lu C, Li M. Mir-152 inhibits cell proliferation and colony formation of CD133(+) liver cancer stem cells by
targeting KIT. Tumour Biol 2015;36:921-8.
50 Chai S, Ng KY, Tong M, Lau EY, Lee TK, et al. Octamer 4/microRNA-1246 signaling axis drives Wnt/β-catenin activation in liver
cancer stem cells. Hepatology 2016;64:2062-76.
51 Wilson GS, Hu Z, Duan W, Tian A, Wang XM, et al. Efficacy of using cancer stem cell markers in isolating and characterizing liver
cancer stem cells. Stem Cells Dev 2013;22:2655-64.
52 Chen Y, Yu D, Zhang H, He H, Zhang C, et al. CD133(+)EpCAM(+) phenotype possesses more characteristics of tumor initiating cells
in hepatocellular carcinoma Huh7 cells. Int J Biol Sci 2012;8:992-1004.
53 Song W, Li H, Tao K, Li R, Song Z, et al. Expression and clinical significance of the stem cell marker CD133 in hepatocellular carcinoma.
Int J Clin Pract 2008;62:1212-8.
54 Sasaki A, Kamiyama T, Yokoo H, Nakanishi K, Kubota K, et al. Cytoplasmic expression of CD133 is an important risk factor for overall